Data demonstrates the performance of OVASight in a low prevalence population- 89% Specificity, 91% Sensitivity and a Negative Predictive Value of 99.6% for the management of suspected Benign Pelvic ...

Biosimilars offer increased patient choice and potential cost-savings, compared with originator biologics. We studied 3 years of prescribed biologics among US physician practices to determine the ...

Artificial intelligence (AI) models can generate scientific abstracts that are difficult to distinguish from the work of human authors. The use of AI in scientific writing and performance of AI ...

Data from 20 abstracts demonstrate value of company’s blood tests across the continuum of cancer care, including: screening, therapy selection, residual and recurrent disease detection, and ...

CINCINNATI, May 19, 2021 (GLOBE NEWSWIRE) -- Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO) announced that Aadi Bioscience (“Aadi”), a privately-held biopharmaceutical company focusing on ...

NASHVILLE, Tenn.--(BUSINESS WIRE)--Today, Sarah Cannon announced it will present its latest cancer research insights at the American Society of Clinical Oncology’s (ASCO®) Annual Meeting being held ...

Presentations highlight full data from dose-escalation stage of Phase 1/2 clinical trial in Ewing sarcoma and interim data from Advanced Solid Tumor (AST) trial Initial drug activity observed in both ...

A new drug could become the first ever targeted brain cancer treatment, with encouraging early results from a phase 1 trial suggesting it could treat some patients with advanced disease. Two of the ...

Melanoma Updates From ASCO 2023: PD-1 and LAG-3 Jeffrey S. Weber, MD, PhD, discusses updates related to melanoma practice and care from ASCO 2023. Experts And Viewpoints, October 24, 2023 Society for ...